Stock
Ownership of a fraction of a corporation and the right to claim a share of the corporation's assets and profits equal to the amount of stock owned
US listed security
Listed on NASDAQ
US headquartered
Headquartered in Gaithersburg, Maryland, United States
Novavax, Inc.
$125.48
NVAX
After Hours:
$125.00
(-0.38%)-$0.48
As of Dec 2, 7:59:54 PM GMT-5 · USD · NASDAQ · Disclaimer

In the news

Financial performance
(USD)Q3 2020Year/year change
Revenue
157.02M6,163.42%
Net income
-197.31M-993.55%
Diluted EPS--
Net profit margin-125.66%82.54%
Operating income-193.24M-705.07%
Net change in cash-129.84M-5,532.89%
Cash on hand334.17M369.56%
Cost of revenue294.09M1,480.18%

About

Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III clinical trial in older adults for its candidate vaccine for seasonal influenza, NanoFlu and a candidate vaccine for prevention of COVID-19. Wikipedia
Founded
1987
Employees
522

Key stats

Previous close
The last closing price
$123.47
Day range
The difference between the high and low prices over the past day
$115.51 - $127.87
Year range
The difference between the high and low prices over the past 52 weeks
$3.65 - $189.40
Market cap
A valuation method that multiplies the price of a company's stock by the total number of outstanding shares.
7.99B USD
Volume
The average number of shares traded each day over the past 30 days
4.54M
P/E ratio
The ratio of current share price to trailing twelve month EPS that signals if the price is high or low compared to other stocks
-
Dividend yield
The ratio of annual dividend to current share price that estimates the dividend return of a stock
-
Primary exchange
Listed exchange for this security
NASDAQ

About

Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III clinical trial in older adults for its candidate vaccine for seasonal influenza, NanoFlu and a candidate vaccine for prevention of COVID-19. Wikipedia
Founded
1987
Employees
522

Discover more

You may be interested in
This list is generated from recent searches, followed securities, and related companies.

Google is not an investment adviser and expresses no view with respect to any of the companies included in this list or any securities issued by those companies. Learn more

People also search for

Search
Clear search
Close search
Google apps
Main menu